FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4376643211> ?p ?o ?g. }

• W4376643211 abstract "BACKGROUNDWe previously demonstrated the safety of stereotactic body radiotherapy followed by pembrolizumab (SBRT+P) in patients with advanced solid tumors. This phase I clinical trial was expanded to study the safety of partial tumor irradiation (partial-Rx). We assessed irradiated local failure (LF) and clinical outcomes with correlations to biomarkers including CD8+ T cell radiomics score (RS) and circulating cytokines.METHODSPatients received SBRT to 2-4 metastases and pembrolizumab for up to 7 days after SBRT. Tumors measuring up to 65 cc received the full radiation dose (complete-Rx), whereas tumors measuring more than 65 cc received partial-Rx. Landmark analysis was used to assess the relationship between tumor response and overall survival (OS). Multivariable analysis was performed for RS and circulating cytokines.RESULTSIn the combined (expansion plus original) cohort, 97 patients (219 metastases) were analyzed and received SBRT+P. Forty-six (47%) patients received at least 1 partial-Rx treatment. There were 7 (7.2%)dose-limiting toxicities (DLTs). 1-year LF was 7.6% overall, and 13.3% and 5.4% for partial-Rx and complete-Rx tumors, respectively (HR 2.32, 95% CI 0.90-5.97, P = 0.08). The overall, unirradiated, and irradiated objective response rates were 22%, 12%, and 34%, respectively. Irradiated tumor response to SBRT+P was associated with prolonged OS; 1-year OS was 71% (responders), 42% (mixed-responders), and 0% (nonresponders) (P < 0.01). High-RS was significantly associated with improved LF, progression-free survival (PFS), and OS. Elevated circulating IL-8 was independently associated with inferior PFS and OS.CONCLUSIONSBRT+P is safe in patients with large, advanced solid tumors. Additional studies are warranted to assess noninferiority of complete versus partial irradiation of tumors in the setting of immunotherapy.TRIAL REGISTRATIONClinicaltrials.gov NCT02608385FUNDINGMerck Investigator Studies Program; Hillman Fellows for Innovative Cancer Research Program; NIH grants UM1CA186690-06, P50CA254865-01A1, P30CA047904-32, and R01DE031729-01A1." @default.
• W4376643211 created "2023-05-17" @default.
• W4376643211 creator A5005507588 @default.
• W4376643211 creator A5013622492 @default.
• W4376643211 creator A5019846143 @default.
• W4376643211 creator A5026264123 @default.
• W4376643211 creator A5029884023 @default.
• W4376643211 creator A5038171309 @default.
• W4376643211 creator A5046031005 @default.
• W4376643211 creator A5054855052 @default.
• W4376643211 creator A5055476105 @default.
• W4376643211 creator A5063337705 @default.
• W4376643211 creator A5073604255 @default.
• W4376643211 creator A5081911362 @default.
• W4376643211 creator A5087880055 @default.
• W4376643211 date "2023-05-15" @default.
• W4376643211 modified "2023-10-01" @default.
• W4376643211 title "Partial tumor irradiation plus pembrolizumab in treating large advanced solid tumor metastases" @default.
• W4376643211 cites W1528207664 @default.
• W4376643211 cites W1543675789 @default.
• W4376643211 cites W1845059181 @default.
• W4376643211 cites W1972125775 @default.
• W4376643211 cites W1994826332 @default.
• W4376643211 cites W1997495967 @default.
• W4376643211 cites W1999020268 @default.
• W4376643211 cites W2046834643 @default.
• W4376643211 cites W2054995801 @default.
• W4376643211 cites W2060344107 @default.
• W4376643211 cites W2071433338 @default.
• W4376643211 cites W2075702041 @default.
• W4376643211 cites W2097475056 @default.
• W4376643211 cites W2120079339 @default.
• W4376643211 cites W2123884323 @default.
• W4376643211 cites W2143172913 @default.
• W4376643211 cites W2166459387 @default.
• W4376643211 cites W2298626553 @default.
• W4376643211 cites W2403758065 @default.
• W4376643211 cites W2468308090 @default.
• W4376643211 cites W2528163604 @default.
• W4376643211 cites W2578888194 @default.
• W4376643211 cites W2605630275 @default.
• W4376643211 cites W2606870926 @default.
• W4376643211 cites W2621684067 @default.
• W4376643211 cites W2655262992 @default.
• W4376643211 cites W2756847895 @default.
• W4376643211 cites W2760326418 @default.
• W4376643211 cites W2769016931 @default.
• W4376643211 cites W2787553571 @default.
• W4376643211 cites W2805209851 @default.
• W4376643211 cites W2807552403 @default.
• W4376643211 cites W2809848353 @default.
• W4376643211 cites W2885326465 @default.
• W4376643211 cites W2890875511 @default.
• W4376643211 cites W2926245852 @default.
• W4376643211 cites W2938101988 @default.
• W4376643211 cites W2947927504 @default.
• W4376643211 cites W2950824232 @default.
• W4376643211 cites W2956407134 @default.
• W4376643211 cites W2959186378 @default.
• W4376643211 cites W2965794029 @default.
• W4376643211 cites W2970683397 @default.
• W4376643211 cites W2972293235 @default.
• W4376643211 cites W2981055741 @default.
• W4376643211 cites W3013251573 @default.
• W4376643211 cites W3020886383 @default.
• W4376643211 cites W3021646013 @default.
• W4376643211 cites W3032651552 @default.
• W4376643211 cites W3036285492 @default.
• W4376643211 cites W3037453845 @default.
• W4376643211 cites W3092186599 @default.
• W4376643211 cites W3102138313 @default.
• W4376643211 cites W3152557580 @default.
• W4376643211 cites W3167422454 @default.
• W4376643211 cites W3175162150 @default.
• W4376643211 cites W3207983141 @default.
• W4376643211 cites W3211508047 @default.
• W4376643211 cites W4220655021 @default.
• W4376643211 cites W4220971206 @default.
• W4376643211 cites W4231096603 @default.
• W4376643211 cites W4239330499 @default.
• W4376643211 cites W4240340450 @default.
• W4376643211 cites W4255794139 @default.
• W4376643211 cites W4281810829 @default.
• W4376643211 doi "https://doi.org/10.1172/jci162260" @default.
• W4376643211 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37183819" @default.
• W4376643211 hasPublicationYear "2023" @default.
• W4376643211 type Work @default.
• W4376643211 citedByCount "0" @default.
• W4376643211 crossrefType "journal-article" @default.
• W4376643211 hasAuthorship W4376643211A5005507588 @default.
• W4376643211 hasAuthorship W4376643211A5013622492 @default.
• W4376643211 hasAuthorship W4376643211A5019846143 @default.
• W4376643211 hasAuthorship W4376643211A5026264123 @default.
• W4376643211 hasAuthorship W4376643211A5029884023 @default.
• W4376643211 hasAuthorship W4376643211A5038171309 @default.
• W4376643211 hasAuthorship W4376643211A5046031005 @default.
• W4376643211 hasAuthorship W4376643211A5054855052 @default.
• W4376643211 hasAuthorship W4376643211A5055476105 @default.
• W4376643211 hasAuthorship W4376643211A5063337705 @default.
• W4376643211 hasAuthorship W4376643211A5073604255 @default.

• next